Lee Crystal Man Ying, Huxley Rachel R, Woodward Mark, Zimmet Paul, Shaw Jonathan, Cho Nam H, Kim Hyung Rae, Viali Satu, Tominaga Makoto, Vistisen Dorte, Borch-Johnsen Knut, Colagiuri Stephen
The George Institute for International Health, University of Sydney, Sydney, NSW 2050, Australia.
Diabetes Res Clin Pract. 2008 Sep;81(3):377-80. doi: 10.1016/j.diabres.2008.05.011. Epub 2008 Jul 9.
To compare the prevalence of metabolic syndrome (MetS) by combinations of MetS components derived from the National Cholesterol Education Program Adult Treatment Panel III (ATPIII) and International Diabetes Federation (IDF) definitions.
Four studies with ethnically distinct populations from the Asia-Pacific region were selected from the DETECT-2 study database. The prevalences of combinations of MetS components using the modified ATPIII (modATPIII) and IDF MetS definitions were compared between sexes and across populations.
A total of 22,952 participants from Australia, Japan, Korea and Samoa were included. The age-adjusted prevalence of modATPIII MetS varied from 9.4 to 35.8% in men and 10.3 to 57.2% in women; results for IDF were generally higher. Prevalences of the 16 possible MetS component combinations from the modATPIII definition that result in a diagnosis of MetS ranged from 0 to 12.7%. Of those with IDF-defined abdominal obesity, the prevalences of the 11 IDF-defined MetS component combinations ranged from 0.2 to 18.3%.
The large variation in the prevalence of possible MetS component combinations to diagnose MetS may explain the different risk of cardiovascular outcomes associated with MetS in different populations, especially since particular combinations of MetS components are associated with different risk of cardiovascular disease.
比较根据美国国家胆固醇教育计划成人治疗组第三次报告（ATPIII）和国际糖尿病联盟（IDF）定义得出的代谢综合征（MetS）各组分组合的MetS患病率。
从DETECT-2研究数据库中选取了四项来自亚太地区、种族不同人群的研究。使用改良的ATPIII（modATPIII）和IDF的MetS定义，比较了不同性别和不同人群中MetS各组分组合的患病率。
共纳入了来自澳大利亚、日本、韩国和萨摩亚的22,952名参与者。年龄调整后的modATPIII MetS患病率在男性中为9.4%至35.8%，在女性中为10.3%至57.2%；IDF定义的患病率总体上更高。根据modATPIII定义可诊断为MetS的16种可能的MetS组分组合的患病率在0至12.7%之间。在IDF定义的腹型肥胖者中，11种IDF定义的MetS组分组合的患病率在0.2%至18.3%之间。
用于诊断MetS的可能的MetS组分组合患病率差异很大，这可能解释了不同人群中与MetS相关的心血管结局风险不同的原因，特别是因为MetS各组分的特定组合与不同的心血管疾病风险相关。
